Cytoskeletal active agents for glaucoma therapy
US5798380A · kind A · utility
68Cited by
3References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 21, 1996 |
| Grant date | Aug 25, 1998 |
| Priority date | — |
| Expiry date | Feb 21, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for the treatment of glaucoma are described. The compounds described cause a perturbation of cell adhesions in the trabecular meshwork, mainly via disruption of the associated cytoskeletal structures or the modulation of their interactions with the underlying membrane. Perturbation of these adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.